Biovica International

Biovica International AB is a biotechnology company based in Uppsala, Sweden, focused on developing and commercializing blood-based biomarker assays to enhance cancer therapy monitoring and predict patient outcomes, primarily in breast cancer. Its flagship product, DiviTum, measures the activity of the enzyme thymidine kinase-1 in blood serum, providing critical insights into cell proliferation and therapy effectiveness. The assay has demonstrated its capabilities in clinical trials, allowing for early evaluation of treatment responses. Biovica collaborates with leading cancer institutes and pharmaceutical companies to advance next-generation therapies. The company holds ISO 13485 certification for Quality Management Systems, and DiviTum is CE-labeled and MPA-registered, ensuring compliance with regulatory standards. Since its incorporation in 2008, Biovica has aimed to facilitate optimal treatment strategies from the outset of cancer care.